Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Gilead feels the heat as close al­ly Gala­pa­gos re­ports a big set­back on one of their top ex­per­i­men­tal drugs

The bad news keeps stack­ing up at Gala­pa­gos — which quite like­ly just lost con­trol of a bil­lion-dol­lar deal — and by ex­ten­sion their close part­ners at Gilead.

The biotech $GLPG re­port­ed af­ter the bell Thurs­day that GLPG1972, one of their top de­vel­op­ment pro­grams, flat failed a mid-stage study for os­teoarthri­tis, flunk­ing the pri­ma­ry and all sec­ondary end­points.

Test­ing 3 dif­fer­ent dos­es of their drug, which re­lies on ADAMTS-5 in­hi­bi­tion, in­ves­ti­ga­tors con­clud­ed that none of them trig­gered a sta­tis­ti­cal­ly sig­nif­i­cant re­sponse — as mea­sured by car­ti­lage thick­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.